| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Esophageal sphincter device for gastroesophageal reflux disease.
|
N Engl J Med
|
2013
|
5.41
|
|
2
|
Prevalence and risk factors for ischemia, leak, and stricture of esophageal anastomosis: gastric pull-up versus colon interposition.
|
J Am Coll Surg
|
2004
|
2.82
|
|
3
|
Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial.
|
Am J Gastroenterol
|
2003
|
2.63
|
|
4
|
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).
|
Ann Surg
|
2015
|
2.61
|
|
5
|
Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.
|
J Am Coll Surg
|
2003
|
2.36
|
|
6
|
Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells.
|
Cell Stem Cell
|
2013
|
2.23
|
|
7
|
Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison.
|
Am J Gastroenterol
|
2006
|
2.07
|
|
8
|
Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial.
|
Am J Gastroenterol
|
2003
|
1.84
|
|
9
|
Enteryx implantation for GERD: expanded multicenter trial results and interim postapproval follow-up to 24 months.
|
Gastrointest Endosc
|
2005
|
1.62
|
|
10
|
Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis.
|
J Thorac Oncol
|
2012
|
1.61
|
|
11
|
Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers.
|
Clin Gastroenterol Hepatol
|
2003
|
1.48
|
|
12
|
Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients.
|
J Am Coll Surg
|
2006
|
1.47
|
|
13
|
Eosinophilic esophagitis with severe GERD.
|
Am J Gastroenterol
|
2009
|
1.47
|
|
14
|
Atypical variants of classic achalasia are common and currently under-recognized: a study of prevalence and clinical features.
|
J Am Coll Surg
|
2011
|
1.41
|
|
15
|
Bile exposure inhibits expression of squamous differentiation genes in human esophageal epithelial cells.
|
Ann Surg
|
2012
|
1.40
|
|
16
|
Physiologic basis for the treatment of epiphrenic diverticulum.
|
Ann Surg
|
2002
|
1.37
|
|
17
|
Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology.
|
J Gastrointest Surg
|
2004
|
1.37
|
|
18
|
Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
|
Am J Gastroenterol
|
2002
|
1.33
|
|
19
|
A new era in esophageal diagnostics: the image-based paradigm of high-resolution manometry.
|
J Am Coll Surg
|
2009
|
1.28
|
|
20
|
Pathogenesis of Barrett esophagus: deoxycholic acid up-regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells.
|
Arch Surg
|
2007
|
1.27
|
|
21
|
Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens.
|
J Am Coll Surg
|
2010
|
1.24
|
|
22
|
The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells.
|
J Gastrointest Surg
|
2007
|
1.21
|
|
23
|
Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel.
|
J Am Coll Surg
|
2013
|
1.16
|
|
24
|
Esophageal perforation: surgical, endoscopic and medical management strategies.
|
Curr Opin Gastroenterol
|
2010
|
1.16
|
|
25
|
Hiatal hernia, lower esophageal sphincter incompetence, and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease.
|
J Gastrointest Surg
|
2008
|
1.15
|
|
26
|
Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication.
|
J Gastrointest Surg
|
2002
|
1.13
|
|
27
|
The mutagenic potential of duodenoesophageal reflux.
|
Ann Surg
|
2005
|
1.08
|
|
28
|
En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus.
|
Arch Surg
|
2004
|
1.05
|
|
29
|
Preoperative lower esophageal sphincter pressure affects outcome of laparoscopic esophageal myotomy for achalasia.
|
J Gastrointest Surg
|
2004
|
1.02
|
|
30
|
HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
|
Mod Pathol
|
2011
|
1.01
|
|
31
|
A population-based analysis of emergent vs. elective hospital admissions for an intrathoracic stomach.
|
Surg Endosc
|
2009
|
0.99
|
|
32
|
Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome.
|
J Gastrointest Surg
|
2007
|
0.99
|
|
33
|
Surgical resection for locoregional esophageal cancer is underutilized in the United States.
|
J Am Coll Surg
|
2010
|
0.99
|
|
34
|
Esophageal stenting for malignant and benign disease: 133 cases on a thoracic surgical service.
|
Ann Thorac Surg
|
2011
|
0.98
|
|
35
|
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
|
J Thorac Cardiovasc Surg
|
2003
|
0.98
|
|
36
|
BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis.
|
J Clin Invest
|
2015
|
0.96
|
|
37
|
Perioperative risk of laparoscopic fundoplication: safer than previously reported-analysis of the American College of Surgeons National Surgical Quality Improvement Program 2005 to 2009.
|
J Am Coll Surg
|
2012
|
0.95
|
|
38
|
Barrett's esophagus in females: a comparative analysis of risk factors in females and males.
|
Am J Gastroenterol
|
2005
|
0.95
|
|
39
|
Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.
|
Clin Cancer Res
|
2011
|
0.94
|
|
40
|
Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa.
|
Arch Surg
|
2005
|
0.94
|
|
41
|
Update on fundoplication for the treatment of GERD.
|
Curr Gastroenterol Rep
|
2012
|
0.93
|
|
42
|
Achalasia of the esophagus: a surgical disease.
|
J Am Coll Surg
|
2008
|
0.92
|
|
43
|
Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma.
|
BMC Gastroenterol
|
2012
|
0.90
|
|
44
|
Molecular determinants in targeted therapy for esophageal adenocarcinoma.
|
Arch Surg
|
2006
|
0.90
|
|
45
|
Gastrectomy as a remedial operation for failed fundoplication.
|
J Gastrointest Surg
|
2007
|
0.90
|
|
46
|
Vagal-sparing esophagectomy: a more physiologic alternative.
|
Ann Surg
|
2002
|
0.89
|
|
47
|
Association of kyphosis and spinal skeletal abnormalities with intrathoracic stomach: a link toward understanding its pathogenesis.
|
J Am Coll Surg
|
2009
|
0.89
|
|
48
|
Physiologic mechanism and preoperative prediction of new-onset dysphagia after laparoscopic Nissen fundoplication.
|
J Gastrointest Surg
|
2002
|
0.89
|
|
49
|
The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma.
|
Ann Thorac Surg
|
2004
|
0.89
|
|
50
|
Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR).
|
J Gastrointest Surg
|
2008
|
0.88
|
|
51
|
Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer.
|
J Gastrointest Surg
|
2009
|
0.87
|
|
52
|
Should elective repair of intrathoracic stomach be encouraged?
|
J Gastrointest Surg
|
2009
|
0.87
|
|
53
|
Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus.
|
World J Surg
|
2003
|
0.87
|
|
54
|
Improvement in educational effectiveness of morbidity and mortality conferences with structured presentation and analysis of complications.
|
J Surg Educ
|
2010
|
0.86
|
|
55
|
Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells.
|
Surgery
|
2009
|
0.85
|
|
56
|
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.
|
J Gastrointest Surg
|
2004
|
0.85
|
|
57
|
Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
|
Surgery
|
2013
|
0.85
|
|
58
|
Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells.
|
Ann Surg
|
2014
|
0.85
|
|
59
|
Dysphagia postfundoplication: more commonly hiatal outflow resistance than poor esophageal body motility.
|
Surgery
|
2012
|
0.84
|
|
60
|
Endoscopic management of early esophageal neoplasia: an emerging standard.
|
J Gastrointest Surg
|
2011
|
0.83
|
|
61
|
Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus.
|
Arch Surg
|
2004
|
0.83
|
|
62
|
A current assessment of endoluminal approaches to the treatment of gastroesophageal reflux disease.
|
Surg Innov
|
2004
|
0.81
|
|
63
|
Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions.
|
Arch Pathol Lab Med
|
2011
|
0.81
|
|
64
|
Treatment strategies for esophageal cancer.
|
Gastroenterol Clin North Am
|
2013
|
0.81
|
|
65
|
Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
|
Surgery
|
2005
|
0.81
|
|
66
|
Towards the molecular characterization of disease: comparison of molecular and histological analysis of esophageal epithelia.
|
J Gastrointest Surg
|
2007
|
0.81
|
|
67
|
Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies.
|
BMC Gastroenterol
|
2014
|
0.80
|
|
68
|
Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
|
Int J Cancer
|
2006
|
0.79
|
|
69
|
The management of dysplastic Barrett's esophagus: where do we go from here?
|
Ann Surg Oncol
|
2002
|
0.79
|
|
70
|
Minimally invasive surgery for esophageal cancer.
|
Surg Oncol Clin N Am
|
2013
|
0.79
|
|
71
|
Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus.
|
Am J Gastroenterol
|
2006
|
0.78
|
|
72
|
Esophageal sphincter device for gastroesophageal reflux disease.
|
N Engl J Med
|
2013
|
0.78
|
|
73
|
Laparoscopic Nissen fundoplication assessment: task analysis as a model for the development of a procedural checklist.
|
Surg Endosc
|
2008
|
0.78
|
|
74
|
The Durability of Endoscopic Therapy for Treatment of Barrett's Metaplasia, Dysplasia, and Mucosal Cancer After Nissen Fundoplication.
|
J Gastrointest Surg
|
2015
|
0.77
|
|
75
|
Minimally invasive surgery for esophageal motility disorders.
|
Surg Clin North Am
|
2002
|
0.77
|
|
76
|
Reflux-associated oxygen desaturations: usefulness in diagnosing reflux-related respiratory symptoms.
|
J Gastrointest Surg
|
2012
|
0.77
|
|
77
|
Evaluation of esophageal function for antireflux surgery.
|
Gastrointest Endosc Clin N Am
|
2005
|
0.76
|
|
78
|
Getting it "just right": the continued dilemma of the ideal treatment of Barrett's esophagus with early neoplasia.
|
Gastrointest Endosc
|
2008
|
0.76
|
|
79
|
The role of lymphadenectomy in the surgical treatment of esophageal and gastric cancer.
|
Curr Probl Surg
|
2012
|
0.76
|
|
80
|
Carcinogenesis in reflux disease--in search for bile-specific effects.
|
Microsurgery
|
2007
|
0.76
|
|
81
|
Bile acid at low pH reduces squamous differentiation and activates EGFR signaling in esophageal squamous cells in 3-D culture.
|
J Gastrointest Surg
|
2013
|
0.76
|
|
82
|
Excellent quality of life after Nissen fundoplication depends on successful elimination of reflux symptoms and not the invasiveness of the surgical approach.
|
Ann Thorac Surg
|
2002
|
0.76
|
|
83
|
Barrett's esophagus: now what?
|
Ann Surg
|
2003
|
0.75
|
|
84
|
Progress in outlining the frequency and risk of recurrent neoplasia after ablation of Barrett's esophagus.
|
Gastrointest Endosc
|
2010
|
0.75
|
|
85
|
Surgical management of hypertensive lower esophageal sphincter with dysphagia or chest pain.
|
J Gastrointest Surg
|
2003
|
0.75
|
|
86
|
Controversies in the current therapy of carcinoma of the esophagus.
|
J Am Coll Surg
|
2002
|
0.75
|
|
87
|
The origins of an operation: a brief history of transhiatal esophagectomy.
|
Ann Surg
|
2009
|
0.75
|
|
88
|
Adenocarcinoma of the gastroesophageal junction: benefits of an extended lymphadenectomy.
|
Surg Oncol Clin N Am
|
2006
|
0.75
|
|
89
|
24-h multichannel intraluminal impedance-pH monitoring may be an inadequate test for detecting gastroesophageal reflux in patients with mixed typical and atypical symptoms.
|
Surg Endosc
|
2014
|
0.75
|
|
90
|
Modern surgery for esophageal cancer.
|
Gastroenterol Clin North Am
|
2008
|
0.75
|
|
91
|
Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease.
|
Thorac Surg Clin
|
2005
|
0.75
|
|
92
|
Letter to the editors.
|
J Gastrointest Surg
|
2007
|
0.75
|
|
93
|
Surgical innovation and diseases of the foregut.
|
Surg Innov
|
2004
|
0.75
|